Phase 1 Phenylketonuria Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men and women between 18 and 45 years old, with at least 3 participants of each gender included in the study groups.
- People with a body mass index (a measure of body weight relative to height) between 19 and 26, where men weigh at least 50 kg and women weigh at least 45 kg.
- People who are willing to sign a consent form after being fully informed about the risks and procedures involved in the research.
- People who are willing to use reliable contraception for 3 months after the last dose, and who have no plans to become pregnant or donate sperm or eggs during that time.
Who may not be able to join:
- People with a family history of sudden death or serious mental or neurological conditions.
- People with significant ongoing health conditions, such as problems absorbing nutrients from food, or chronic liver, kidney, heart, or hormonal disorders.
- People with abnormal liver or kidney function, a kidney filtration rate below a certain level, an abnormal heart rhythm measurement on an ECG, or who test positive for certain infectious diseases.
- People with known drug allergies, a history of drug misuse, or who have recently taken part in another clinical trial.
- People who drink alcohol, smoke, consume grapefruit or amino acid supplements, or have an irregular daily routine during the screening period.
- Women who are pregnant or breastfeeding, or people who are unable to tolerate blood draws or who faint at the sight of needles.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 15131190710
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse events and clinical safety indicators after a single dose.; Change in QT/QTc interval correction ΔΔQTc after dosing.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.